Application of Watson for Oncology in Hepatocellular Carcinoma Surgery
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Enrollment
- 150
- Locations
- 1
- Primary Endpoint
- Operative outcomes
Study Overview
Brief Summary
The aim of this study was to evaluate the surgical decisions of Watson artificial intelligence in patients with hepatocellular carcinoma.
Detailed Description
Hepatectomy is an effective treatment for patients with hepatocellular carcinoma, but liver failure after hepatectomy may lead to increased postoperative mortality. Therefore, it is very important to make preoperative surgical decisions, evaluate the safety of the operation and identify which patients are likely to suffer from liver failure. The artificial intelligence platform developed by IBM Watson for Watson tumor treatment decisions can provide treatment decisions and corresponding theoretical basis to guide surgical decisions based on the key clinical data of liver cancer patients.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Other
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •18 years≤ Age ≤80 years
- •Compling with the diagnosis criteria of complex hepatic carcinoma.
- •Primary hepatic carcinoma without intrahepatic or extrahepatic extensive cancer metastasis, the metastatic hepatic carcinoma whose primary focal has been controlled
- •Preoperative liver function is Child - Pugh grade A or B.
- •The patients are volunteered for the study.
Exclusion Criteria
- •Patients with mental illness.
- •Patients can't tolerate the operation owe to a variety of basic diseases (such as severe cardiopulmonary insufficiency, renal insufficiency, cachexia and blood system diseases, etc.)
- •The patients refused to take part in the study.
- •There are other co-existed malignant tumors.
- •Benign liver diseases
Outcomes
Primary Outcomes
Operative outcomes
Time Frame: intraoperative
Operative outcomes such as operative time, estimated blood loss and blood transfusion were recorded.
Secondary Outcomes
- Postoperative survival(3 years)